First-in-Human Trial Readiness in Latin America: The Cross-Functional Gate Before Submission

A first-in-human (FIH) study in Latin America can move quickly only when the sponsor’s evidence tells one consistent story. The protocol, risk analysis, investigator brochure or device dossier, informed-consent materials, ethics package, and import plan must describe the same intended use, population, procedure, and safeguards. If those documents drift apart, a fast regulatory pathway can turn into a long clarification cycle.

Internal experience across early-stage programs shows that readiness is less about producing more pages and more about closing the handoffs between regulatory, clinical, quality, site, and supply-chain teams. This practical gate helps MedTech founders and regulatory directors test whether a study is ready for country submissions without relying on a single calendar estimate.

1. Start with one study story

Before country tailoring begins, write a concise study narrative that every contributor can use. State what the investigational device is, who will use it, for which patients, in what setting, and what the FIH study is designed to learn. Separate proof-of-principle or early-feasibility questions from claims that will require a later pivotal study or market authorization.

Then link each major claim to evidence. A risk control in the technical file should appear in the protocol’s monitoring plan and, where relevant, in the training and consent materials. The primary endpoint should match the feasibility objective. The procedure described for the investigator should match the version assessed by the ethics committee. This simple traceability exercise exposes contradictions before an authority or committee has to ask about them.

• Intended use: define the population, setting, operator, procedure, and boundaries of use.
• Risk controls: show foreseeable hazards, mitigations, stopping rules, and escalation contacts.
• Clinical objective: use a focused endpoint set that answers the early-stage question without promising more than the study can demonstrate.
• Participant protection: connect eligibility, follow-up, adverse-event handling, and consent language to the risk profile.
• Version control: maintain one controlled source for device specifications, protocol revisions, and country annexes.

2. Map the regulatory and ethics lanes before filing

Latin America is not one regulatory pathway. A country matrix should identify the competent authority, ethics route, submission format, required translations, import documentation, responsible local party, and the definition of a complete submission. It should also distinguish a statutory or published review period from a practical activation forecast that includes clarifications, contracts, training, and shipment.

Brazil illustrates why this distinction matters. Law No. 14.874/2024 establishes a 30-business-day period for an ethics committee to issue its opinion after accepting a complete document set, and a 90-business-day ceiling for the health analysis of primary clinical-trial petitions covered by the law. Those provisions are useful planning inputs, but they do not eliminate sponsor work before acceptance or operational work after authorization. The official English translation of Law No. 14.874/2024 should be checked for scope and the current implementation context.

Colombia requires a different document conversation. INVIMA’s clinical-investigation materials identify the technical and ethical information needed for medical-device studies and publish current forms for protocol evaluation, ethics-committee assessment, notifications, and periodic reports. The sponsor should confirm the latest checklist rather than reusing a prior country’s format. The INVIMA clinical-investigation page is the appropriate starting point for current requirements.

3. Treat site and import readiness as submission evidence

An approved protocol cannot enroll if the site cannot perform the procedure, protect participants, or receive the investigational product. Site feasibility should therefore be documented before submission, not treated as a post-approval procurement task. Confirm investigator experience, procedure volume, equipment, imaging or laboratory support, emergency coverage, data systems, and the site’s ability to meet the visit schedule.

For an investigational device, also map the physical journey into the country. Identify the importer of record or other responsible local party, customs broker, shipping documents, product description, packaging, storage conditions, and receipt inspection. The receiving site should know who can release a shipment, where it will be stored, how it will be labeled, and how deviations will be documented. If those answers are missing, the regulatory package is operationally incomplete even when the PDF set looks finished.

Use an owner-and-dependency map for each handoff. Regulatory owns the submission matrix; clinical owns protocol and endpoint consistency; quality owns controlled versions and deviation pathways; the site owns readiness evidence; and logistics owns import and delivery controls. A single accountable person should resolve conflicts rather than allowing parallel teams to submit different answers.

4. Run a documented readiness gate

Two weeks before the planned filing, hold a cross-functional gate with the country team and proposed site. The objective is not to read every page aloud. It is to test the few dependencies that can stop the study.

• Traceability check: reconcile intended use, device configuration, endpoints, risks, and consent language across all core documents.
• Completeness check: confirm forms, translations, signatures, fees, certificates, and local representative details for the target country.
• Site check: verify staff training, equipment, standard operating procedures, safety escalation, and recruitment assumptions.
• Import check: test the shipment dossier with the broker and receiving site before the first dispatch.
• Clarification check: prepare an evidence map showing who will answer likely questions and how quickly.

Record open items with an owner, due date, and submission impact. If a high-risk item is unresolved, move the filing date rather than hiding the issue inside an optimistic timeline. A short, coherent dossier usually creates more speed than a large dossier assembled in parallel without a common source of truth.

Frequently asked questions

What is the most common FIH readiness failure?
Document inconsistency is a frequent failure: the protocol, device description, risk controls, and consent materials describe different versions of the study. A traceability matrix finds this before submission.

Can a sponsor use the same dossier in every Latin American country?
The scientific core can be reused, but country forms, translations, ethics routes, local responsibilities, and import rules require tailored annexes. Reuse controlled content; do not assume identical filing requirements.

When should import planning begin?
Begin during site selection and protocol planning. Shipment classification, local responsibility, customs documents, storage, and receipt procedures can affect the activation sequence and should be tested before authorization.

For sponsors planning an early-stage MedTech study, the practical goal is a submission that regulators, ethics committees, investigators, and logistics partners can all execute from the same study story. That is the readiness gate that turns a promising FIH concept into a controllable Latin America launch plan.